Board of Directors
The Institute for Pediatric Innovation’s board of directors is comprised of officers from its consortium hospitals and experts in healthcare innovation.
Assistant VP of Strategic and Business Planning, Texas Children's Hospital
Paola Álvarez-Malo is the Assistant Vice President of Strategic and Business Planning at Texas Children’s Hospital. She joined Texas Children’s in 2009 after eight years in strategic and business planning in the Energy industry. During her time at TCH, she has led organization-wide efforts in Strategic Planning and Business Process Transformation. Specifically, Paola has contributed to the upcoming expansions of Texas Children’s Hospital - The Woodlands and the high acuity clinical services in the Texas Medical Center to meet the demand of the growing Houston population. Her current focus includes developing the Commercialization and Innovation Office at Texas Children’s in order to identify creative solutions to meet the needs of the hospital’s patients, both present and future. Paola has an undergraduate degree from Stanford University and a Master of Science from Boston University. Paola is active in various community-based parent organizations as well and is a volunteer with the Stanford Alumni network and the Houston Area Women’s Center.
Anthony Atala, M.D.
Director, Wake Forest Institute for Regenerative Medicine
Anthony Atala, M.D., is the Director of the Wake Forest Institute for Regenerative Medicine, and the Chair of the Department of Urology at Wake Forest School of Medicine. He is a practicing surgeon and a researcher in the area of regenerative medicine. He is Editor-in-Chief of Stem Cells-Translational Medicine and Therapeutic Advances in Urology, and serves on the editorial boards of 20 journals. Tony is a recipient of many awards, including the Christopher Columbus Foundation Award, bestowed on a living American who is currently working on a discovery that will significantly affect society; and the World Technology Award in Health and Medicine. He was named as one of Fast Company's 100 Most Creative People in Business. In 2011, he was elected to the Institute of Medicine of the National Academies. Tony heads a team of approximately 300 physicians and researchers. Ten applications of technologies developed in Tony’s laboratory have been used clinically. He has applied for or received over 200 patents.
Director of Technology Management, University Hospitals
Stephen Behm has over 20 years of industry experience in research, product development, marketing, and business development. He is currently the Director of Technology Management at University Hospitals in Cleveland, Ohio where he leads the organization’s efforts to commercialize medical technology developed by its clinical staff. Prior to that he was a principal in three start-up organizations, two where he worked with the growth of early stage technology, marketing, sales, and business development programs at large and small biomedical organizations, and another that was an early stage orthopedics company. Previously, he was Vice President of Business Development and Marketing for Biomec where he was responsible for technology licensing, strategic partnerships, marketing and sales. Before that, he was Director of Business Services for the Edison BioTechnology Center, where his responsibilities included funding programs for start-up ventures, technology transfer, and general business assistance. Earlier, he was Director of Product Development and Marketing for Amresco, an international supplier of biochemicals, pharmaceutical intermediaries and in-vitro diagnostics.
Patricia Bondurant, DNP, RN
CEO, WRP32 Management Comany; Co-Founder, TransForm Healthcare Consulting
Patricia Bondurant has served in numerous leadership roles in the NICU and 0-3 pediatric developmental arena throughout most of her career. Pattie has been recently appointed the CEO of WRP32 Management Company and has co-founded TransForm Healthcare Consulting. She is currently engaged in working with several national initiatives supporting the care of neonates in the NICU and in developing products for Women and Children’s health as well as workplace safety.
Prior to her appointment as CEO and starting her consulting company, Pattie has served as the Vice President for Nursing for the Newborn Center and Women’s Services at Texas Children’s Hospital as well as the Senior Clinical Director of the NICU at Cincinnati Children’s Hospital. During this time, Pattie also had the opportunity to serve as the clinical and executive lead of The Greater Cincinnati Beacon Program, one of the most recognized and successful federally funded, regional Quality Improvement and Health Information Technology programs in the country.
Pattie has extensive experience building and leading interprofessional teams to improve care and outcomes for critically ill neonates, children and women. She has been involved in and has lead several infrastructure redesigns under nursing and within the NICU and Women’s Services.
Before taking on more formal nursing leadership roles, Pattie was a practicing Clinical Nurse Specialist. She is the recipient of hospital, regional and national recognition and awards for her nursing and quality leadership and has published and presented broadly. She received her Bachelor’s degree from Skidmore College, her Master’s in Nursing as a Clinical Nurse Specialist from the University of Washington and her Doctorate in Nursing Practice from Waynesburg University.
CEO, Supportive Therapeutics
BJ Bormann currently serves as the CEO of Supportive Therapeutics, a Cambridge, MA based company that is developing a new drug to treat oral mucositis in oncology patients. Prior to this current engagement, Dr. Bormann held biotechnology positions as the CEO of Harbour Antibodies, the CEO of Pivot Pharmaceuticals (PVTF) and the Chief Business Analysts for Nanomedical Systems. She also has almost 25 years in large pharm serving in senior executive positions in Licensing and Business development at Boehringer Ingelheim as Senior Vice President and Pfizer, as Vice President. Dr. Bormann serves on the board of directors of various companies, including Supportive Therapeutics, Bioline Rx (NASDAQ-BLRX) and the Institute for Pediatric Innovation. Dr. Bormann received her Ph.D. in Biomedical Science from the University of Connecticut Health Center and her B. Sc. from Fairfield University in Biology. Dr. Bormann completed postdoctoral training at Yale Medical School in the department of pathology.
Kevin M. Considine
Partner, Considine & Furey, LLP
Mr. Considine has a well established litigation-based, business law practice with a concentration in government law. Since 1990, he has worked in private practice providing legal representation and consulting services to business clients on diverse matters involving litigation, legislation and regulatory law.
Prior to entering private practice, Mr. Considine was employed by the Massachusetts State Senate, serving as legal counsel to the Committee on Government Regulations from 1985 to 1990. From 1980 to 1984, he was employed by the Massachusetts House of Representatives and served as staff director of the Joint Committee on Energy.
Mr. Considine operated his own legal/lobbying firm for seventeen years before merging it with Brown Rudnick, LLP, where he led the firm’s Massachusetts Government Law and Strategies Group practice.
Mr. Considine has extensive civil and criminal trial experience. His practice areas include contracts, commercial and business litigation, commercial arbitration, and appellate advocacy. He has represented clients in the automotive, banking, energy, environmental, gaming, hospitality, real estate, and telecommunications industries. Mr. Considine is a graduate of the University of Massachusetts and Suffolk University Law School.
Jonathan J. Fleming
President and CEO, Q-State Biosciences
Mr. Fleming is the President and CEO of Q-State Biosciences, an early stage privately funded neuroscience company in Cambridge MA. Q-State uses its proprietary technology platform to enable the discovery of new medicines for diseases such as ALS, epilepsy, Parkinson's Disease and neuropathic pain. Prior to his work at Q-State, Mr. Fleming was President of NEHI (Network for Excellence in Health Innovation) a nonprofit, non-partisan health policy institute focused on enabling innovations that improve the quality and lower the costs of health care. Since 1996, Mr. Fleming has been the Managing Partner of Oxford Bioscience Partners, an international venture capital firm specializing in life science investments, based in Boston, MA. Mr. Fleming has been in the investment business for more than 31 years, starting and financing growth companies in the United States, Europe, Israel and Asia. Prior to joining Oxford Bioscience Partners in 1996, he was a Founding General Partner of MVP Ventures in Boston, MA. He began his investment career with TVM Techno Venture Management in Munich, Germany. Mr. Fleming also co-founded Medica Venture Partners, a venture capital investment firm specializing in early stage health care and biotechnology companies in Israel, and the Korea Seoul Life Science Fund, based in Seoul, Korea. Mr. Fleming is a director of Leerink Partners, a Boston based investment bank specializing in health care companies, and several other private companies. In addition, Mr. Fleming has been a Senior Lecturer at the MIT Sloan School of Management since 2002, where he co-teaches a class on business strategy for life science managers. Mr. Fleming holds a Master's degree in Public Administration from Princeton University’s Woodrow Wilson School of Public and International Affairs, and a Bachelor's degree in Political Science from the University of California, Berkeley.
Paul Pereira, JD
Associate Director of Patient Advocacy, Vertex Pharmaceutical
As Associate Director for Patient Advocacy at Vertex Pharmaceuticals, Paul Pereira works closely with the cystic fibrosis community to support the needs of patients with policymakers across the country. Paul has over twenty years’ experience working for payers and the pharmaceutical industry on health policy issues. He began his career working for Blue Cross & Blue Shield of Rhode Island and then transitioned to Tap Pharmaceuticals where he was responsible for managing Government Affairs activities for the Rocky Mountain States. Mr. Pereira was then Senior Director for Government Affairs at AstraZeneca Pharmaceuticals where he managed a team a Government Affairs Professionals representing the Eastern part of the US. Throughout the course of his career, Paul has been engaged in health policy issues in 40 states. Paul holds a B.A. in Economics and a J.D. from the University of Massachusetts, Dartmouth.
Paul and his wife Kara live in Rhode Island with their three young boys.
Charlette Stallworth, MBA
VP, Strategic Partnerships at Stanford Children’s Health
Charlette Stallworth, MBA has served as VP, Strategic Partnerships at Stanford Children’s Health since 2016 where she spearheads development and growth of partnerships that advance SCH’s mission of providing excellent pediatric healthcare. Charlette also serves as an instrumental leader in technology transfer and innovation, and she has completed the Innovative Health Care Leader course at the Stanford Graduate School of Business. Charlette has previously been responsible for securing business relationships and agreements for clinical trials, licensing, and commercialization of intellectual property with pharmaceutical and medical device companies on behalf of the largest not-for-profit healthcare system in Texas. Prior to focusing on healthcare innovation, Charlette held positions in capital finance at Scott & White Healthcare, commercial banking at BBVA Compass and JPMorgan Chase, and as a commissioned officer in the United States Army.
Lawrence S. Wagner, CFA, CFP
Vice President, Rockland Trust Financial Services
Larry Wagner is responsible for developing fiduciary, investment management and retirement plan business in Rhode Island and Southcoast Massachusetts for Rockland Trust Company’s Investment Management Group. Larry began his financial services career in 1987 with Old Stone Trust Company. He joined Rockland Trust Company in 2008 from Firstfed Trust Company/Webster Bank where he had been since the formation of Firstfed Trust Company in 2000. Larry holds FINRA Series 6, 7 & 63 securities licenses and insurance licenses for Life, Accident, and Health in addition to the CFP® and CFA designations. Larry is a Past President and current Board Member of the Providence Society of Financial Analysts, Board Member of The Partnership for Philanthropic Planning of RI, member of the Estate Planning Council of RI & RI Financial Planning Association. Larry graduated from Denison University with a BA in Economics.